Blume Capital Management’s Biogen BIIB Stock Holding History

Blume Capital Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25	Closed	-$7.12K	–	317
2023 Q2	$7.12K	Sell	25 -29	-54%	-$8.63K	﹤0.01%	262
2023 Q1	$15K	Buy	54 +26	+93%	+$7.19K	﹤0.01%	222
2022 Q4	$7.75K	Hold	28	–	–	﹤0.01%	261
2022 Q3	$7K	Sell	28 -56	-67%	-$11.9K	﹤0.01%	255
2022 Q2	$17K	Buy	84 +11	+15%	+$2.25K	0.01%	222
2022 Q1	$15K	Buy	73 +45	+161%	+$9.79K	﹤0.01%	231
2021 Q4	$7K	Hold	28	–	–	﹤0.01%	264
2021 Q3	$8K	Hold	28	–	–	﹤0.01%	261
2021 Q2	$10K	Hold	28	–	–	﹤0.01%	235
2021 Q1	$8K	Buy	+28	New	+$7.55K	﹤0.01%	228
2015 Q2	–	Sell	-110	Closed	-$46K	–	246
2015 Q1	$46K	Buy	110 +60	+120%	+$23.6K	0.03%	135
2014 Q4	$17K	Buy	+50	New	+$16.2K	0.01%	211

Other funds holding BIIB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Blume Capital Management's BIIB Position: Q3 2023 in Review

Blume Capital Management sold out of Biogen (BIIB) in Q3 2023, closing a stake of 25 shares — an estimated $7.12K sold.

Blume Capital Management first reported a position in BIIB in Q4 2014 and held it in 12 quarters. The position peaked at $46K in Q1 2015. 965 funds tracked by Wall St. Rank hold BIIB as of Q3 2023.

Blume Capital Management reported no remaining Biogen position as of Q3 2023 after selling out during the quarter.
Blume Capital Management sold 25 Biogen shares in Q3 2023, an estimated $7.12K.
Blume Capital Management first reported a position in Biogen in Q4 2014 and held it in 12 quarters.
Blume Capital Management's Biogen position peaked at $46K in Q1 2015.
965 funds tracked by Wall St. Rank held Biogen as of Q3 2023.

Based on Blume Capital Management's 13F filing for Q3 2023, filed 3 Nov 2023.